Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Concurrent Inhibition of The RAS Pathway and Autophagy As a Treatment Approach for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...
The MarketWatch News Department was not involved in the creation of this content. Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor ...
Morning Overview on MSN
Scientists uncover genetic switch that makes pancreatic cancer chemo-proof
Researchers at Duke-NUS Medical School have identified a molecular switch controlled by the protein GATA6 that determines ...
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the ...
Gen1e Lifesciences Inc. has disclosed drugs targeting extracellular-regulated kinase (ERK) reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune and lung diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results